Clinical Trial Results: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism [Phase 4]

View source ↗

Summary

Phase 4 trial comparing bleeding risk between rivaroxaban and apixaban for treatment of venous thromboembolism; results posted and study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Venous Thromboembolism | Phase 4 | Status: COMPLETED | Results posted: 2026-06-24